"Breast cancer" + "Biomarker" = 11.643

Based on (Wang et al 2021) using ELISA detection system, serum SEMA4c levels were higher in BC than in benign tumor or normal patients

BC (7.46 ± 2.69 ng/ml)

benign tumors (3.51 ± 1.60 ng/ml)

Normal (3.19 ± 0.96 ng/ml)

Optimal cut value to diagnose BC was (5.00 ng/ml) based on selected population

Increased serum SEMA4C levels exhibit high accuracy in discriminating early stage BC and DCIS from controls

AUC 0.879 (95% CI: 0.832-0.925)

74.1% Sensitivity

89.7% Specifity

Based on (Ding et al 2023) using WGCNA from extracted data on GEO revealed that MME was positively related to but negatively related to BRCA to which this indicates MME as diagnostic biomarker as MME expression is decreased in breast tumor tissues, as MME was significantly reduced in luminal B and infiltrating ductal carcinoma

theory leads that circulating autoantibodies in SLE exert anticancer effects against BRCA, although MME expression is also identified in other cancers

MME level was significantly decreased in tumor tissues with corresponding noncancerous tissues

AUC 0.984 (95% CI: 0.976-0.992)

Based on (Balatti et al 2018) n